Neoadjuvant Keytruda (pembrolizumab) and AC for early triple-negative breaat cancer – pro
Although combined immuno anad chemotehrapy is standard in beast cancer, the chemo that had been studied was ccarboplatin and paclitaxel, not AC. Pemrolizumab and AC are not listed by NCCN.
P.Schmid et al, . Pembrolizumab for Early Triple-Negative Breast Cancer. February 27, 2020 N Engl J Med 2020; 382:810-821
Schmid P, Cortes J, Dent R, Pusztai L, McArthur H, Kümmel S, Bergh J, Denkert C, Park YH, Hui R, Harbeck N, Takahashi M, Untch M, Fasching PA, Cardoso F, Andersen J, Patt D, Danso M, Ferreira M, Mouret-Reynier MA, Im SA, Ahn JH, Gion M, Baron-Hay S, Boileau JF, Ding Y, Tryfonidis K, Aktan G, Karantza V, O’Shaughnessy J; KEYNOTE-522 Investigators. Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer. N Engl J Med. 2022 Feb 10;386(6):556-567
NCCN Breast Cancer 2022, BINV-L2